TrialAnnals of the rheumatic diseases2011

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.

Vibeke Strand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.